Inhibikase Therapeutics, Inc. (NYSE:IKT - Get Free Report)'s share price dropped 6.6% on Thursday . The company traded as low as $1.80 and last traded at $1.85. Approximately 138,020 shares were traded during trading, a decline of 33% from the average daily volume of 204,541 shares. The stock had previously closed at $1.98.
Inhibikase Therapeutics Stock Performance
The stock has a fifty day simple moving average of $1.88 and a two-hundred day simple moving average of $2.14. The stock has a market capitalization of $132.33 million, a price-to-earnings ratio of -0.67 and a beta of 0.92.
Hedge Funds Weigh In On Inhibikase Therapeutics
Institutional investors have recently modified their holdings of the business. Soleus Capital Management L.P. purchased a new stake in shares of Inhibikase Therapeutics during the fourth quarter worth $20,556,000. Fairmount Funds Management LLC purchased a new stake in Inhibikase Therapeutics during the fourth quarter valued at about $19,906,000. ADAR1 Capital Management LLC purchased a new stake in Inhibikase Therapeutics during the fourth quarter valued at about $16,585,000. Nantahala Capital Management LLC purchased a new stake in shares of Inhibikase Therapeutics in the 4th quarter valued at $7,118,000. Finally, Blackstone Inc. bought a new position in shares of Inhibikase Therapeutics during the fourth quarter valued at about $6,730,000. 3.81% of the stock is owned by institutional investors.
About Inhibikase Therapeutics
(
Get Free Report)
Inhibikase Therapeutics, Inc, a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract.
Further Reading
Before you consider Inhibikase Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inhibikase Therapeutics wasn't on the list.
While Inhibikase Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
